Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-06-25 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 25, 2020, for Moleculin Biotech, Inc. It reports a Regulation FD Disclosure about a press release related to a presentation at the AACR Annual Meeting. The document includes a press release as an exhibit and does not contain detailed financial statements or substantive financial data. The length is 4273 characters, which is relatively short and primarily serves as an announcement of the press release and presentation. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or releases without detailed financial data.
2020-06-25 English
FORM 4
Director's Dealing
2020-06-17 English
FORM 4
Director's Dealing
2020-06-17 English
FORM 4
Director's Dealing
2020-06-17 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Moleculin Biotech, Inc. dated June 11, 2020. It contains information about changes in board compensation policy (Item 5.02), and detailed voting results from the 2020 Annual Meeting of Stockholders (Item 5.07). The presence of detailed vote counts and descriptions of proposals voted on at the Annual Meeting indicates this is an official declaration of voting results. The document is not a full annual report, audit report, or earnings release, but specifically reports the outcomes of shareholder votes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6940 characters) and content confirm it is not merely an announcement of a report but the actual voting results report.
2020-06-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 16, 2020, by Moleculin Biotech, Inc. It announces an event related to a press release about antiviral testing results. The document is short (3284 characters) and primarily serves to announce the press release, which is attached as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full report or detailed financial data. It is not an earnings release, annual report, or any other specific report type but a current report announcing an event and attaching a press release.
2020-06-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.